No Prescription |
 |
 | ||
|
Ethinyloestradiol Generic Estrace |
|
| ||
No Prescription » Prescription Drugs 7 » Ethinyloestradiol Generic Estrace IndicationsPostmenopausal symptoms due to oestrogen deficiency including prevention of postmenopausal osteoporosis. In women with an intact uterus the addition of a progestogen is essential.Treatment of metastatic breast cancer in postmenopausal women.Treatment of prostatic cancer.Dosage and AdministrationThis will depend on the particular indication used but treatment should be undertaken with as low a dose as possible and for as short a period as is necessary.Menopausal symptoms: 0.01-0.05mg daily.Osteoporosis: 0.02-0.05mg daily.Prostatic and mammary carcinoma: 1-2mg daily. Buy Ethinyloestradiol Generic Estrace and other Prescription Drugs 7 products online at Medstore. Buy Online at Medstore - Click Here!
About Ethinyloestradiol Generic Estrace: Product Type: Prescription Drugs 7 Ethinyloestradiol ( Generic Estrace Femtrace Gynodiol ) Ethinyloestradiol (Generic Estrace Femtrace Gynodiol) Generic Estrace Femtrace Gynodiol 10mcg 100 Tablets 200(2 x 100) Tablets Generic Estrace Femtrace Gynodiol Ethinyloestradiol
View more Prescription Drugs 7 No Prescription: NEW YORK, Oct. 5, 2011 /PRNewswire via COMTEX/ -- Reportlinker.com announces that a new market research report is available in its catalogue: European Pharmaceutical Market: Strategic Assessments of Leading Suppliers http://www.reportlinker.com/p0651431/European-Pharmaceutical-Market-Strategic-Assessments-of-Leading-Suppliers.html #utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication This report provides industry executives with strategically significant competitor information and analysis of the leading players in the European pharmaceutical market. The report provides a worldwide strategic overview of the pharmaceutical market, including: Sales forecast for major product segments: ethical, OTC, generics. Sales forecast for major drug categories: cardiovascular, gastrointestinal, antibiotic, CNS, respiratory, musculoskeletal, hormonal/genitourinary, dermatological, oncological, ophthalmic, and others. In addition, the report reviews major regulatory, technological, economic, demographic, and social trends with potentially significant impact on the market during the next five years, including discussion of such key issues as pricing, industry consolidation, market globalization, growing R&D cost, generics, as well as advances in genomics, proteomics, drug screening, tissue engineering, bioinformatics, and other technologies. The companies analyzed in this report include Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis and Wyeth.
| ||
